Mixonix, a Farmingdale, New York company that specializes in ultrasonic devices for surgical applications such as osteotomies and debridements, won FDA clearance for the new Nexus surgical platform. The Nexus combines the capabilities of Mixonix’s three existing products, namely BoneScalpel, SonicOne and Sonastar, into a single system that can be used to perform tumor resections, bone corrections, and a whole host of other procedures. It will be made available for purchase in the U.S. next month.
The Nexus is designed to accommodate future ultrasonic devices that the company expects to develop. It is run by the firm’s own algorithm that has been tuned to deliver high power and high efficiency. This allows for faster resections, particularly when working on bone removals.
Mixonix touts the system’s easy touchscreen interface that lets clinicians get on with procedures quickly. “We are very pleased to have achieved this critical approval, marking a significant milestone for Misonix and the culmination of years of hard work,” said Stavros Vizirgianakis, President and CEO of Misonix, in a published statement. “Nexus is a powerful, highly integrated and easy-to-use system that will benefit both healthcare providers and patients by incorporating the latest advances in ultrasonic technology allowing for increased efficiency and efficacy, and thus improved outcomes. It is truly a transformational product. The overwhelmingly positive feedback we have received from the surgeon community since first unveiling Nexus reinforces our confidence in its potential to serve as a significant growth engine for Misonix. Nexus is a key component of our strategy to increase our presence in the neuro, spine, ortho, wound and general surgery markets.”
Product page: Nexus…